

## Detection of Lethal Dose 50 of Biofilm-producing Methicillin-resistant *Staphylococcus aureus* Local Isolate From Mastitis

Abdullah Abdullazeez Khaleel Sheehan<sup>1\*</sup>, Mohammed H.Khudor<sup>2</sup>, Fanar A. Isihak<sup>3</sup>

<sup>1,3</sup> Department of Microbiology, College of Veterinary Medicine, University of Mosul, Mosul, Iraq,

<sup>2</sup> Department of Microbiology, College of Veterinary Medicine, University of Basrah, Basrah, Iraq

\*Corresponding author: abdsheehan@uomosul.edu.iq

Doi: <https://doi.org/10.37940/AJVS.2021.14.2.3>

Received: 2/7/2021 Revised: 6/10/2021 Accepted: 11/10/2021

This article is licensed under a CC BY (Creative Commons Attribution 4.0)

<http://creativecommons.org/licenses/by/4.0/>.

### Abstract

It is very important, before starting the manufacture of any vaccine from any microorganism estimation of LD<sub>50</sub> of that microorganism to determine their pathogenicity and virulence. Estimated LD<sub>50</sub> was very important to be used in challenge tests later to estimate the protection level of the manufactured vaccine in experimental animals. So, this study was aimed to estimate LD<sub>50</sub> of local methicillin-resistant *Staphylococcus aureus* (MRSA) bacterial isolate. A pilot study has been done to determine approximately LD<sub>50</sub> of used MRSA in the study by using different bacterial concentrations of MRSA to determine approximate LD<sub>50</sub> that can be able to kill half numbers of animals used in the study to be used later in the estimation of exact LD<sub>50</sub> by using of Up-and-Down method. Ninety Wistar albino rats have been used for this purpose, eighty-four animals which divided into fourteen groups by six animals for each group (for pilot study) and remained six animals for (Up-and-Down method). The results showed that 9 X 10<sup>10</sup> CFU/ml was lead to killing half numbers of animals used in the study, this dose has been used as starting dose in the Up-and-Down method to estimation of the exact LD<sub>50</sub> dose. The results showed that 5.526 X 10<sup>10</sup> CFU/ml was the exact LD<sub>50</sub> of local MRSA isolate, which will be used later in the challenge test to estimate the protection level of a locally prepared vaccine against MRSA isolate.

**Keywords:** LD<sub>50</sub>, Pilot study, *Staphylococcus aureus*, Biofilm-producing, Methicillin-resistant, Vaccine

### الخلاصة

من المهم جدا قبل البدء في عملية تصنيع اي لقاح من اي كائن مجهري حي قياس الجرعة القاتلة لنصف عدد الحيوانات LD<sub>50</sub> لتحديد امراضه وفوعة ذلك الكائن الحي . ومن المهم ايضا استخدام الجرعة المحسوبة والقاتلة لنصف عدد الحيوانات في اختبار التحدي لاحقا لتحديد مستوى الحماية التي توفرها اللقاح المصنع من ذلك الكائن الحي في الحيوانات المختبرية نتيجة حقن تلك الجرعة . اجريت دراسة مصغرة لتحديد الجرعة التقريبية القاتلة لنصف عدد الحيوانات لجرثومة المكورات العنقودية الذهبية والمعزولة محليا والقادرة على قتل نصف عدد الحيوانات المستخدمة في التجربة لاستخدامها لاحقا في حساب الجرعة القاتلة لنصف عدد الحيوانات LD<sub>50</sub> باستخدام طريقة الصعود والنزول. تم استخدام اربع وثمانون جرذا في الدراسة المصغرة وقسمت الى اربعة عشر مجموعة ثنائية بواقع ستة جرذان لكل مجموعة . تم حقنهم بتركيز مختلفة من العزلة الجرثومية لتحديد الجرعة التقديرية القادرة على قتل نصف عدد الحيوانات المستخدمة في التجربة. بعدها استخدمت ستة جرذان اضافية في تحديد الجرعة الدقيقة القاتلة لنصف عدد الحيوانات بطريقة الصعود والنزول. اثبتت النتائج ان الجرعة التقريبية القادرة على قتل نصف عدد الحيوانات كانت 9 X 10<sup>10</sup> CFU/ml وعند استخدام هذه الجرعة في طريقة الصعود والنزول كجرعة الانطلاق اثبتت النتائج ان الجرعة الدقيقة القاتلة لنصف عدد الحيوانات لجرثومة المكورات العنقودية الذهبية المحلية كانت 5.526 X 10<sup>10</sup> CFU/ml والتي سوف يتم استخدامها لاحقا في اختبار التحدي لقياس مستوى الحماية التي توفرها اللقاح المصنع من العترة الجرثومية لعزلة المكورات العنقودية الذهبية المحلية .

## Introduction

Renewed trials have been effort all over the world to control many infectious diseases by vaccination, among them, *Staphylococcus aureus* is considered an important pathogen both in animals and humans (1). Many trials every year effort to develop new vaccines against *S. aureus* that cause many diseases both in humans and animals, bovine mastitis is considered an important disease that causes more economic loss due to their effect on the mammary glands and dairy industry by decrease milk quality, and bad milk and milk products (2). vaccination is important method to control *S. aureus* infections (3). Lethal dose 50 (LD<sub>50</sub>) defined as a dose lead to dying 50 % of exposed animals to infective microorganism (4). While minimum lethal dose is defined as a lower dose of infective microorganism lead to the observation of mortality (5). LD<sub>50</sub> was used to illation for infectivity of microorganisms (6). It is very important to know LD<sub>50</sub> in any process of new vaccine development against any microorganism. Classical methods such as reed and Muench or recently modified methods were used to estimate the number of CFU in bacterial infection or viral concentration in viral infection to determine their virulence also estimate their immunogenicity (7). From 1920 after the development of LD<sub>50</sub> estimation procedure to now several modifications done to it which included arithmetical modifications done by Reed and Muench 1931, Karber 1931, Lorke,1983, or graphical modifications done by Miller and Tainter 1944, Litchfield and Wilcoxon 1949, revised Up-and-Down procedure OECD 1987 (8). So we aimed by this study to estimation of LD<sub>50</sub> of a local isolate of MRSA bacterial strain from bovine mastitis to use it later in vaccine preparation against it.

## Materials and methods

### Bacterial strain

Local biofilm-producing methicillin-resistant *S. aureus* MRSA isolated from bovine mastitis was used in the study to estimation of it is LD<sub>50</sub>. The bacterial isolate was obtained from central research laboratory, College of Veterinary Medicine, University of Basrah and confirmed as MRSA by (9)

### Bacterial concentrations :

Different bacterial concentrations were prepared according to McFarland standards, these concentrations were estimated by spectrophotometer at OD600 and the results were recorded.

### Animals

Ninty male Wistar albino rats were used, 84 of them were used in a pilot study which they were divided into 14 groups that were treated by different concentrations and volumes of bacterial strain as shown in table (3), whereas remained 6 animals were used in Up-and-down method to estimation LD<sub>50</sub> of the bacterial strain

### McFarland standards

McFarland standards depend on chemical reaction occurred between each of 1 % barium sulfate (Ba<sub>2</sub>Cl.2H<sub>2</sub>O) and 1 % of sulfuric acid (H<sub>2</sub>SO<sub>4</sub>) after mixing them well, this reaction lead to formation of turbidity as a result of barium sulfate precipitation, this turbidity can be compared visually with certain concentration of bacterial suspension. It can be prepared by mixing different volumes from both of them with optimized concentrations for each one in every dilution as shown in table (2) leading to formation of of different degrees of turbidities representing different degrees of bacterial concentrations with specific optical density for each concentration. (10)

**Table (1) Show the component of the McFarland standards and their conc.**

McFarland scale	McFarland turbidity as CFU/ml	1 % Ba Cl <sub>2</sub> .2H <sub>2</sub> O	1 % H <sub>2</sub> SO <sub>4</sub>
0.5	1.5 x 10 <sup>8</sup>	0.05	9.95
1	3 x 10 <sup>8</sup>	0.1	9.9
2	6 x 10 <sup>8</sup>	0.2	9.8
3	9 x 10 <sup>8</sup>	0.3	9.7
4	1.2 x 10 <sup>9</sup>	0.4	9.6
5	1.5 x 10 <sup>9</sup>	0.5	9.5
6	1.8 x 10 <sup>9</sup>	0.6	9.4
7	2.1 x 10 <sup>9</sup>	0.7	9.3
8	2.4 x 10 <sup>9</sup>	0.8	9.2
9	2.7 x 10 <sup>9</sup>	0.9	9.1
10	3.0 x 10 <sup>9</sup>	1	9.0

### Spectrophotometer

Lovibond® trade mark spectrophotometer type (spectrodirect ) was used in the study to measure bacterial concentration using OD600 wavelength.

### Up-and-down method (11,12)

In this method after administration of a dose to the experimental animal, it can be reduced if the animal was died or elevating the dose if the animal was survived and does not respond or exhibited clear clinical signs, allowing to optimum dose titration to get the perfect dose that gives the best results. Clinical signs exhibited by affected animals include increasing respiration rates, abdominal type respiration, abdominal debilitation, sluggishness, absence of response to reflexes, convulsion, tremors, severe muscle spasms, severe lacrimation, cyanosis, ataxia, and depression.

### Pilot study :

A pilot study has been done, 84 male Wistar albino rats at eight weeks of age and 200-225 grams/animal body weight has been used to estimate approximately lethal dose 50 (LD<sub>50</sub>) for

the MRSA bacteria, they were divided into equal 14 groups by six animals for each group, different volumes and concentrations were prepared from the local MRSA, each group of rats were injected by different prepared concentrations with different volumes of MRSA strain by intrapretonial rout I/P as shown in table (3). All animals were breaded as follow :

- 1- Every 6 animals were kept in one cage with labeling each of them with in their cage.
- 2- All the ideal environmental conditions for rearing were set such as temperature, darkness, feeding on concentrated feed, and water-saving.
- 3- Animals were kept under this condition for one week to check the health of animals before starting the study.
- 4- Animals were injected by intraperitoneal I/P route with different bacterial concentrations according to pilot study design.
- 5- Animals were observed for 72 hours and results were recorded.

### Results and Discussion :

#### Bacterial concentrations:

Different bacterial concentrations were prepared according to McFarland standards turbidity, then these prepared concentrations were estimated by spectrophotometer at OD600 wave length, table (2) illustrate different OD600 values for different bacterial concentrations prepared according to McFarland standards turbidity

**Table (2): Different OD600 values that equal for different bacterial concentrations according to McFarland standards**

Bacterial concentrations according to McFarland standards turbidity	Spectrophotometer values at OD600 wavelength
$1.2 \times 10^7$	0.007
$1.2 \times 10^8$	0.136
$1.2 \times 10^9$	0.976
$1.2 \times 10^{10}$	2.238
$3 \times 10^{10}$	2.782
$6 \times 10^{10}$	3.020
$9 \times 10^{10}$	3.496

#### Pilot study results

The result shows that  $9 \times 10^{10}$  CFU/ml bacterial concentration of local isolate MRSA lead to killing 3 of 6 injected animals, while  $6 \times 10^{10}$  CFU/ml of bacterial concentration killed 2 animals of total 6 injected animals, finally,  $3 \times 10^{10}$  of bacterial concentration killed only 1 of total 6 injected animals after 24 hours. All other concentrations do not cause any death of injected animals as shown in table(3).

#### Calculation of LD<sub>50</sub> by using of Up-and-down method :

According to the Up-and-down method, the last concentration that killed the half number of animals was suggested as a default concentration to be used as start dose in the Up-and-down method to calculation LD<sub>50</sub> according to (13) as follow :

According to table 1 and 2 approximately LD<sub>50</sub> dose of local MRSA bacterial isolate was 3.496 OD600 that equal to  $9 \times 10^{10}$  which was used as

a starting dose in the Up-and-down method, this used dose can be reduced if the animal was died or elevated if the animal was survived by  $\pm$  in dose reach to  $2 \times 10^2$ . It has been used 6 animals in this method and the results were as in table (4):

The Up-and-Down method nowadays was used as one of the important methods that take into account the issue of animal welfare because it reduces the number of animals killed (11). It is very important to know approximately lethal dose 50 to start from it by increasing or decreasing 30 % from it to estimate exact LD<sub>50</sub>. It is nowadays one of excellent method can be used to estimate both lethal and or infective doses for tested microorganism. Pathogens of high values LD<sub>50</sub> mean that it has high pathogenicity and need for high doses of vaccine (14). Our result proved that LD<sub>50</sub> of local isolated MRSA was  $5.526 \times 10^{10}$  CFU/ml by using of Up-and-Down method and this is differ something from each of Saganuwan (7) who was referred that LC<sub>50</sub> of *Staphylococcus aureus* (ATCC 29123) strain was  $1.75 \times 10^{10}$  CFU/ml in rats and also Jankie *et al.* (11) who showed that the LD<sub>50</sub> of *S. aureus* (ATCC 29123) strain was  $1.75 \times 10^{10}$  CFU/ml in rats also, this small variation between our results and other authors may explained to a difference in the strain of *S. aureus* used in the study in which we used local MRSA isolate strain in contrast to standard strain use by other authors.

Senna *et al.*(15) revealed that LD<sub>50</sub> of *S. aureus* with Pcl. neo antigens were  $1.1 \times 10^8$  CFU/ml when injected I/P in the mouse, while Gaudreau, *et al.*(16) referred that *S. aureus* with fibrinogen antigens was  $1 \times 10^7$  CFU/ml when the microorganism injected intravenous I/V in mouse also, Haghghat, *et al.*(17) showed LD<sub>50</sub> of *S. aureus* with endotoxin-free PBS antigens was  $5 \times 10^8$  CFU/ml when injected intraperitoneal route I/P in mice. The reason for this difference in the results may due to many factors that affect LD<sub>50</sub> determination such as: whether the determination method is *in vitro* or *in vivo*, pathogenicity degree

of the used microorganism, titration of antigen and antibody levels, a route of microorganism administration was an important factor effect on the result of LD<sub>50</sub> (18). The pathogenicity of any pathogen can change depending on the of the animal used in the experiment (19).

### Conclusion

It was very important to estimate the LD<sub>50</sub> of any microorganism before preparing of vaccine from it. Up and down method was one of the methods concerned with animal welfare as it leads to killing the least number of animals and provides compassion for animals, provided

**Table(3) Show different bacterial concentrations and volumes prepared from local MRSA with their killing effect on different groups**

Group	No .	McFarland standards	Volume of inj.	Death	Live	Death/Live
G1	6	1.2 X 10 <sup>7</sup>	0.5 ml/animal	0	6	0/6
G2	6	1.2 X 10 <sup>8</sup>	0.5 ml/animal	0	6	0/6
G3	6	1.2 X 10 <sup>9</sup>	0.5 ml/animal	0	6	0/6
G4	6	1.2 X 10 <sup>10</sup>	0.5 ml/animal	0	6	0/6
G5	6	3 X 10 <sup>10</sup>	0.5 ml/animal	0	6	0/6
G6	6	6 X 10 <sup>10</sup>	0.5 ml/animal	0	6	0/6
G7	6	9 X 10 <sup>10</sup>	0.5 ml/animal	0	6	0/6
G7	6	1.2 X 10 <sup>7</sup>	1 ml/animal	0	6	0/6
G8	6	1.2 X 10 <sup>8</sup>	1 ml/animal	0	6	0/6
G9	6	1.2 X 10 <sup>9</sup>	1 ml/animal	0	6	0/6
G10	6	1.2 X 10 <sup>10</sup>	1 ml/animal	0	6	0/6
G11	6	3 X 10 <sup>10</sup>	1 ml/animal	1	5	1/5
G12	6	6 X 10 <sup>10</sup>	1 ml/animal	2	4	2/4
G14	6	9 X 10 <sup>10</sup>	1 ml/animal	3	3	3/3

conditional to know the approximate LD<sub>50</sub> to start from it to know exact LD<sub>50</sub> .

### Acknowledgment

The researcher's thanks the University of Mosul/ College of Veterinary Medicine / Department of Microbiology for providing the appropriate facilities to complete the requirements of this research.

### Conflict of Interest

The authors state that there is no conflict of interest.

**Table (4) Show bacterial concentrations used in the Up-and-down method with their effects on used animals to estimate LD<sub>50</sub> of MRSA**

No.	concentration	Result X or O	Symbols that estimate from table values
1-	9 X 10 <sup>10</sup>	X ↓	X
2-	7 X 10 <sup>10</sup>	X ↓	X
3-	5 X 10 <sup>10</sup>	O ↑	O
4-	7 X 10 <sup>10</sup>	X ↓	X
5-	5 X 10 <sup>10</sup>	O ↑	O
6-	7 X 10 <sup>10</sup>	X	X

O : Remaining live with no effect      X:  
Killing effect (Death)

According to Up-and-down method LD<sub>50</sub> calculated as follow :

LD<sub>50</sub> value =  $xf + K d$ , Xf = The last dose used

K = table value, d = (± in dose)

Symbols XXOXOX from table value was ( - 0.737 ), LD<sub>50</sub> =  $7 \times 10^{10} + (- 0.737) ( 2 \times 10^{10} )$   
= **5.526 X 10<sup>10</sup>**

**5.526 X 10<sup>10</sup>** was equal to 2.941 OD 600 at spectrophotometer

**7 X 10<sup>10</sup>** was equal to 3.185 OD 600 at spectrophotometer

### References

1. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX™, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. *Vaccine*. 2004 Feb 17;22(7):880-

7. <https://doi.org/10.1016/j.vaccine.2003.11.034>
2. Raza A, Muhammad G, Sharif S, Atta A. Biofilm producing Staphylococcus aureus and bovine mastitis: a review. *Molecular microbiology research*. 2013 Apr 10;3(1).DOI:10.5376/mmr.2013.03.0001
3. Pellegrino M, Giraud J, Raspanti C, Odierno L, Bogni C. Efficacy of immunization against bovine mastitis using a Staphylococcus aureus avirulent mutant vaccine. *Vaccine*. 2010 Jun 17;28(28):4523-8.doi: [10.1016/j.vaccine.2010.04.056](https://doi.org/10.1016/j.vaccine.2010.04.056).
4. Kim R, Faisal M. Comparative susceptibility of representative Great Lakes fish species to the North American viral hemorrhagic septicemia virus sublineage IVb. *Diseases of aquatic organisms*. 2010 Jul 26;91(1):23-34.doi: [10.3354/dao02217](https://doi.org/10.3354/dao02217). PMID: 20853739.
5. Kothary MH, Babu US. Infective dose of foodborne pathogens in volunteers: a review. *Journal of food safety*. 2001 May;21(1):49-68.doi:10.1111/j.17454565.2001.tb00307.x
6. McKenney DG, Kurath G, Wargo AR. Characterization of infectious dose and lethal dose of two strains of infectious hematopoietic necrosis virus (IHNV). *Virus research*. 2016 Mar 2;214:80-9.<https://scholarworks.wm.edu/vimsarticles/810>
7. Saganuwan SA. Application of median lethal concentration (LC 50) of pathogenic microorganisms and their antigens in vaccine development. *BMC Research Notes*. 2020 Dec;13(1):1-6.<https://doi.org/10.1186/s13104-020-05126-x>
8. Saganuwan SA. A modified arithmetical method of Reed and Muench for determination of a relatively ideal median lethal dose (LD50). *African Journal of*

- Pharmacy and Pharmacology. 2011 Sep 29;5(12):1543-6.[DOI:10.5897/AJPP11.393](https://doi.org/10.5897/AJPP11.393) .  
<https://www.researchgate.net/publication/266031972>
9. Idbeis H.I. Molecular Analysis of *Staphylococcus aureus* Isolated From Mastitis and Study Their Biofilm Activity Against Cinnamon Oil. PH.D Thesis, Microbiology Department Veterinary Medicine, University of Basrah, 2019.
  10. Isenberg HD. Clinical microbiology procedures handbook. American Society of Microbiology; 1992.
  11. Jankie S, Jenelle J, Suepaul R, Pereira LP, Akpaka P, Adebayo AS, Pillai G. Determination of the infective dose of *Staphylococcus aureus* (ATCC 29213) and *Pseudomonas aeruginosa* (ATCC 27853) when injected intraperitoneally in Sprague Dawley rats. Journal of Pharmaceutical Research International. 2016 Dec 3:1-1.
  12. Paramveer SD, Chanchal KM, Mavani P, Asha R, Shrivastava B, Nema RK. Effective alternative methods of LD50 help to save number of experimental animals. Journal of Chemical and Pharmaceutical Research. 2010;2(6):450-3.[ISSN No: 0975-7384](https://doi.org/10.1146/annurev.pa.20.040180.002301)
  13. Dixon WJ. Efficient analysis of experimental observations. Annual review of pharmacology and toxicology. 1980 Apr;20(1):441-62.[doi:10.1146/annurev.pa.20.040180.002301](https://doi.org/10.1146/annurev.pa.20.040180.002301)
  14. Sharma P, Sihag RC. Pathogenicity test of bacterial and fungal fish pathogens in *Cirrihinus mrigala* infected with EUS disease. Pakistan Journal of Biological Sciences. 2013 Oct 15;16(20):1204.. [doi:10.3923/pjbs.2013.1204.1207](https://doi.org/10.3923/pjbs.2013.1204.1207).
  15. Senna JP, Roth DM, Oliveira JS, Machado DC, Santos DS. Protective immune response against methicillin resistant *Staphylococcus aureus* in a murine model using a DNA vaccine approach. Vaccine. 2003 Jun 2;21(19-20):2661-6.[doi:10.1016/s0264-410x\(02\)00738-7](https://doi.org/10.1016/s0264-410x(02)00738-7)
  16. Gaudreau MC, Lacasse P, Talbot BG. Protective immune responses to a multi-gene DNA vaccine against *Staphylococcus aureus*. Vaccine. 2007 Jan 15;25(5):814-24.[doi:10.1016/j.vaccine.2006.09.043](https://doi.org/10.1016/j.vaccine.2006.09.043)
  17. Haghghat S, Siadat SD, Sorkhabadi SM, Sepahi AA, Sadat SM, Yazdi MH, Mahdavi M. Recombinant PBP2a as a vaccine candidate against methicillin-resistant *Staphylococcus aureus*: immunogenicity and protectivity. Microbial pathogenesis. 2017 Jul 1;108:32-9.[doi:10.1016/j.micpath.2017.04.037](https://doi.org/10.1016/j.micpath.2017.04.037)
  18. Markowitz F. All biology is computational biology. PLoS biology. 2017 Mar 9;15(3):e2002050. [doi:10.1371/journal.pbio.2002050](https://doi.org/10.1371/journal.pbio.2002050)
  19. Casadevall A. The pathogenic potential of a microbe. Msphere. 2017 Jan 1;2(1):e00015-17.[doi:10.1128/msphere.00015-17](https://doi.org/10.1128/msphere.00015-17)